Skip to content

The effect of oxelidine on intraoperative hypoxemia in obese patients undergoing hysteroscopic surgery: A randomized, controlled, double-blind, non-inferiority trial

The effect of oxelidine on intraoperative hypoxemia in obese patients undergoing hysteroscopic surgery: A randomized, controlled, double-blind, non-inferiority trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128719
Enrollment
Unknown
Registered
2026-07-24
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyoxemia

Interventions

Sufentanil group:intravenous injection Sufentanil (0.1 micrograms per kilogram)
Oliceridine group:intravenous injection Oliceridine (20 micrograms per kilogram)

Sponsors

Xiangyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Agree to participate in this study and sign the informed consent form; 2.ASA grade I to III, age > =18 and =30kg/m²; 3.schedule for hysteroscopic surgery;

Exclusion criteria

Exclusion criteria: 1.There were neuropsychiatric system diseases such as schizophrenia, epilepsy and Parkinson's disease before the operation; 2.Those who are unable to cooperate in completing the preoperative neuropsychological assessment (as assessed by the MMSE scale, those with illiteracy 30); 5.Patients with severely impaired functions of vital organs such as the liver and kidneys, liver and kidney insufficiency (Child-PughB/C or eGFR<30mL/min); 6.Preoperative SpO2<90%;

Design outcomes

Primary

MeasureTime frame
The incidence of hypoxemia;

Secondary

MeasureTime frame
The incidence of severe hypoxemia;Body response during cervical dilation.;Intraoperative respiratory and hemodynamic indicators;postoperative advers events;

Countries

China

Contacts

Public ContactZhang Xiaodong

Xiangyang Central Hospital

zxd948785@sina.com+86 719 568 9073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026